Zoriah Aziz1, Weng Kit Huin2, Muhammad Danish Badrul Hisham2, Jia Xin Ng2. 1. Department of Pharmacy, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia. Electronic address: zoriah@um.edu.my. 2. Department of Pharmacy, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia.
Abstract
OBJECTIVE: To present a systematic review of randomised controlled trials examining the effects of pomegranate (Punica granatum) on lipid profiles. METHOD: The Cochrane Central Register of Controlled Trials, MEDLINE, CINAHL, EMBASE, SCOPUS and conference proceedings were searched for relevant trials to June 2019. We included randomized controlled trials comparing pomegranate with placebo. The outcomes examined were effects on lipids level. Two authors screened titles for inclusion, extracted data and assessed the quality of the trials using the revised Cochrane risk of bias tool. We used a random effects model to pool data and stratified trials to examine sources of statistical heterogeneity. To assess the quality of the evidence, we used the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. RESULTS: Seventeen trials recruiting 763 subjects met the inclusion criteria. These trials varied in terms of the dosage form of pomegranate used, subjects recruited and trials duration. Meta-analyses of data did not show pomegranate produced a significant effect on the lipids level examined. The quality of evidence for all outcomes was low due to the imprecision of the pooled effect and the inconsistency within the included trials. The limited data on safety suggest only mild, transient and infrequent adverse events with the short-term use of pomegranate. CONCLUSION: Current evidence does not show pomegranate has significant effects on serum lipid levels. The quality of evidence is poor to support the increasing use of pomegranate for hyperlipidaemia.
OBJECTIVE: To present a systematic review of randomised controlled trials examining the effects of pomegranate (Punica granatum) on lipid profiles. METHOD: The Cochrane Central Register of Controlled Trials, MEDLINE, CINAHL, EMBASE, SCOPUS and conference proceedings were searched for relevant trials to June 2019. We included randomized controlled trials comparing pomegranate with placebo. The outcomes examined were effects on lipids level. Two authors screened titles for inclusion, extracted data and assessed the quality of the trials using the revised Cochrane risk of bias tool. We used a random effects model to pool data and stratified trials to examine sources of statistical heterogeneity. To assess the quality of the evidence, we used the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. RESULTS: Seventeen trials recruiting 763 subjects met the inclusion criteria. These trials varied in terms of the dosage form of pomegranate used, subjects recruited and trials duration. Meta-analyses of data did not show pomegranate produced a significant effect on the lipids level examined. The quality of evidence for all outcomes was low due to the imprecision of the pooled effect and the inconsistency within the included trials. The limited data on safety suggest only mild, transient and infrequent adverse events with the short-term use of pomegranate. CONCLUSION: Current evidence does not show pomegranate has significant effects on serum lipid levels. The quality of evidence is poor to support the increasing use of pomegranate for hyperlipidaemia.
Authors: Javad Sharifi-Rad; Cristina Quispe; Carla Marina Salgado Castillo; Rodrigo Caroca; Marco A Lazo-Vélez; Halyna Antonyak; Alexandr Polishchuk; Roman Lysiuk; Petro Oliinyk; Luigi De Masi; Paola Bontempo; Miquel Martorell; Sevgi Durna Daştan; Daniela Rigano; Michael Wink; William C Cho Journal: Oxid Med Cell Longev Date: 2022-02-21 Impact factor: 6.543